CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE

Their core work

CVBF is an Italian research consortium specializing in paediatric pharmacology and the development of research infrastructure for children's medicines. They work on building networks and tools that enable clinical trials for drugs in children, adolescents, and neonates — a historically underserved area where most medicines are used off-label. Their core contribution is bridging the gap between drug development science and the regulatory/clinical frameworks needed to test medicines safely in young populations. They also contribute to rare disease research and translational medicine platforms.

What they specialise in

How they've shifted over time

CVBF's early H2020 work (2016–2018) focused squarely on paediatric translational research and training — building the foundational knowledge base through projects like SMART and the infrastructure design of ID-EPTRI. From 2018 onward, their focus broadened into large-scale clinical trial networks (c4c), data infrastructure, and rare disease programmes, reflecting a shift from capacity-building to operational deployment. Their most recent project, AMELIE (2020), marks a surprising pivot into regenerative medicine for adult conditions, suggesting willingness to apply their pharmacological expertise beyond paediatrics.

CVBF is moving from designing paediatric research infrastructure toward operating within large clinical networks and diversifying into regenerative medicine — expect them to seek partners in data management, cell therapy, and multi-site clinical coordination.

How they like to work

CVBF operates primarily as a participant and third-party expert in large consortia — 220 unique partners across 39 countries indicate they are deeply embedded in Europe's paediatric research ecosystem. They coordinated one infrastructure design project (ID-EPTRI) but typically contribute specialist knowledge rather than leading. Their involvement as a third party in c4c suggests they serve as an expert advisory body that larger consortia call upon for domain-specific pharmacological expertise.

Extensive European network spanning 220 unique partners across 39 countries, built largely through participation in major paediatric research initiatives like c4c and EJP RD. Their reach is pan-European with strong connections to clinical research institutions and regulatory bodies.

What sets them apart

CVBF occupies a rare niche as a dedicated consortium for biological and pharmacological evaluation, specifically oriented toward paediatric medicines — an area where regulatory requirements are strict and expertise is scarce. Their combination of infrastructure design experience (ID-EPTRI coordinator) and membership in the largest European paediatric clinical trial networks makes them a credible partner for any project needing to include a paediatric dimension. For consortium builders, they bring both the scientific depth and the established network connections to navigate the complex landscape of children's medicine development.

Highlights from their portfolio

• ID-EPTRI
  Their only coordinated project — designed the blueprint for a European Paediatric Translational Research Infrastructure, positioning CVBF as an architect of paediatric research frameworks.
• c4c
  One of Europe's largest paediatric clinical trial networks (2018–2025), where CVBF serves as a third-party expert, reflecting their recognized authority in the field.
• AMELIE
  Their highest-funded project (EUR 797,887) and a departure from paediatrics into regenerative medicine for faecal incontinence, signalling expertise diversification.